Abstract:Erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage stimulating factor (GM-CSF) are currently licensed for use in cancer patients and play a significant role in the management of anemia and neutropenia following myeloblative chemotherapy. EPO was the first recombinant hematopoietic growth factor to be used clinically after a number of clinical trials which demonstrated its effectiveness in treating mild to moderate cancer-associated anemia with or without concomitant chemotherapy (particulary cisplatin). An extensive research has been made for the improvement of the quality of life with EPO therapy, however, when formally assessed, variable effects of this important treatment have been observed. Recently, EPO has been shown to significantly accelerate hematopoietic reconstitution after peripheral blood stem cell transplantation (PBSCT) resulting in reduced infection rates. Both, G-CSF and GM-CSF have been shown, in numerous trials, to shorten the period of chemotherapy-induced neutropenia, with reduction in attendant morbidity and to mobilize PBSC. In addition, administration of both cytokines after PBSCT significantly reduced the use of antibiotics and duration of hospitalization suggesting an economic benefit. The narrower therapeutic window of GM-CSF at higher doses accounts for the fact that it is used much less frequently than G-CSF. To date, none of the growth factors used clinically has been shown to stimulate thrombopoiesis. Although thrombopoietin (TPO) has been found to induce megakaryocyte differentiation in vitro, it is unlikely to enter routine clinical use for treatment of post-chemotherapy thrombocytopenia, since results of clinical trials are not very encouraging, mainly because TPO is difficult to schedule and platelet aggregation may occur. Recently, innovative chimeric growth factor receptor agonists have been synthesized. Synthokine (SC-55494) (a high-affinity human IL-3 receptor ligand analog), myelopoietin (MPO) (activates human IL-3 and G-CSF receptors) and promegapoietin (PMP) (stimulates the human IL-3 and c-mpl receptors) were found to be multilineage hematopoietic growth factors and are currently undergoing clinical trials. Preliminary results suggest that these compounds may have a major impact on the management of myeloablative chemotherapy because of their ability to enhance platelet recovery in addition to their neutrophil restorative activity.

Stimulatory effects of neopterin on hematopoiesis in vitro are mediated by activation of stromal cell function

Negative Feedback on the Effects of Stem Cell Factor on Hematopoiesis is Partly Mediated Through Neutral Endopeptidase Activity on Substance P: a Combined Functional and Proteomic Study

Effects of Preprotachykinin‐I Peptides on Hematopoietic Homeostasis: A Role for Bone Marrow Endopeptidases

The Dynamics of Bone Marrow Stromal Cells in the Proliferation of Multipotent Hematopoietic Progenitors by Substance P: an Understanding of the Effects of a Neurotransmitter on the Differentiating Hematopoietic Stem Cell.

Crosstalk Between Neurokinin Receptors is Relevant to Hematopoietic Regulation: Cloning and Characterization of Neurokinin-2 Promoter

Norepinephrine Stimulates Mobilization of Endothelial Progenitor Cells after Limb Ischemia

Effect of the Culture Supernatams of Interleukin-2-activated Peripheral Blood, Bone Marrow and Cord Blood Mononuclear Cells on Hematopoiesis.

Effects Of Sp(1-4) On Cobblestone-Forming Cells. Implications For Endopeptidases As Hematopoietic Regulators

Use of Neopterin as a Bone Marrow Hematopoietic and Stromal Cell Growth Factor in Tissue-Engineered Devices

Induction of Preprotachykinin-I and Neurokinin-1 by Adrenocorticotropin and Prolactin. Implication for Neuroendocrine-Immune-hematopoietic Axis

The Effects of Natural Killer-Cell Depletion on Ex Vivo Expansion of Hematopoietic Progenitor Cells from Umbilical Cord Blood.

The Nucleolar Protein Nucleophosmin Is Physiologically Secreted by Endothelial Cells in Response to Stress Exerting Proangiogenic Activity Both In Vitro and In Vivo

Neuropeptide Y stimulates osteoblastic differentiation and VEGF expression of bone marrow mesenchymal stem cells related to canonical Wnt signaling activating in vitro

Stimulation of mouse hematopoietic stem cells by angiogenin and DNA preparations

Platelet-Derived Microparticels Stimulate Proliferation of Colony-Forming Unit Granulocyte-Macrophage of Umbilical Cord Blood Hematopoietic Stem Cells.

Effect of synthetic osteogenic growth peptide on hematopoiesis in normal mice and assay of its hematological activity in vitro

Human hematopoietic growth factors: old lessons and new perspectives

Effects of Novel Human Chemokine-Like Factor 1 (CKLF1) on Bone Marrow Hematopoietic Stem Cell/progenitor Cell in Vitro.

Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery

Effects of Stem Cell Factor in Combination with Erythropoietin on Erythropoiesis in Patients with Anemia Associated with Non-Hodgkin's Lymphoma

Leptin receptor + cells promote bone marrow innervation and regeneration by synthesizing nerve growth factor